Biomed Industries Reports Phase 2 Success for Oral Obesity Drug NA-931 at ADA 2025
核心洞察
Biomed Industries (搜索) completed Phase 2 trials of NA-931, a first-in-class oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors for obesity treatment.
The randomized, double-blind, placebo-controlled trial demonstrated weight loss outcomes comparable to leading injectable therapies while showing significantly fewer and milder side effects.
NA-931 achieved weight reduction without muscle loss in adults with obesity or overweight patients with weight-related comorbidities, offering a potential oral alternative to current injectable treatments.
Biomed Industries (搜索) has announced successful completion of Phase 2 clinical trials for NA-931, a novel oral quadruple receptor agonist designed to treat obesity without the need for injections. The company will present these results at the American Diabetes Association's 85th Scientific Sessions in Chicago on June 20-23, 2025.
Phase 2 Trial Design and Results
The Phase 2 study was conducted as a randomized, double-blind, placebo-controlled, parallel-arm clinical trial evaluating NA-931 in adults with obesity (BMI ≥30 kg/m²) or overweight individuals (BMI ≥27 kg/m²) with at least one weight-related comorbidity. Completed in April 2025, the trial assessed safety, tolerability, efficacy, pharmacodynamics, and pharmacokinetics of the investigational drug.
According to Biomed Industries (搜索), NA-931 achieved weight loss outcomes comparable to leading approved and late-stage injectable therapies while demonstrating significantly fewer and milder side effects. The drug showed the ability to reduce body weight without muscle loss, a significant advantage in obesity treatment.
Novel Mechanism of Action
NA-931 represents a first-in-class oral quadruple receptor agonist that targets IGF-1, GLP-1, GIP, and glucagon receptors simultaneously. This multi-targeted approach addresses the complex biological mechanisms underlying obesity, potentially offering advantages over current single or dual-target therapies.
"We believe the future of obesity treatment lies in safe, effective, and accessible oral therapies," said Dr. Lloyd Tran, CEO of Biomed Industries (搜索). "NA-931 is a first-in-class innovation that provides an oral alternative to injectable drugs."
Addressing Global Obesity Crisis
The development comes at a critical time as obesity affects more than 650 million people worldwide. The condition is associated with serious comorbidities including type 2 diabetes, cardiovascular disease, non-alcoholic liver disease, and chronic kidney disease. Projections indicate that by 2035, more than 4 billion people—over 50% of the global population—will be overweight or obese.
Research Connections to Alzheimer's Disease
Biomed Industries (搜索) is also exploring potential mechanistic links between obesity and Alzheimer's disease through its dual development programs. The company will present a scientific poster at ADA 2025 titled "Association Between Alzheimer's Disease (AD) and Obesity: Clinical Trial Results of NA-831 for AD and NA-931 for Obesity," highlighting research that positions the team among the first to identify possible connections between these conditions.
Clinical Development Pipeline
Beyond obesity treatment, Biomed Industries (搜索) maintains an investigational pipeline targeting multiple therapeutic areas including Alzheimer's disease, major depressive disorder, metabolic dysfunction-associated steatohepatitis (MASH), stroke, alcohol use disorder, and rare diseases such as Rett Syndrome and Fragile X syndrome.
The topline Phase 2 data for NA-931 remain under embargo and will be revealed during Dr. Tran's presentation at the ADA Scientific Sessions, the world's largest conference on diabetes and metabolic disorders, expected to draw over 11,000 attendees including physicians, scientists, and pharmaceutical industry leaders.